Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

AG Mortgage Investment Trust Inc MITT

Alternate Symbol(s):  MITT.P.A | MITT.P.B

AG Mortgage Investment Trust, Inc. is a residential mortgage real estate investment trust (REIT). The Company is focused on investing in a diversified, risk-adjusted portfolio of residential mortgage-related assets in the United States mortgage market. The Company's objective is to provide attractive risk-adjusted returns to its stockholders over the long-term, primarily through dividends and capital appreciation. The Company's investment portfolio includes Residential Investments and Agency residential mortgage-backed securities (RMBS). Its residential investments primarily consist of newly originated Non-Agency Loans and Agency-Eligible Loans. In addition to its Residential Investments, the Company also invests in other types of residential mortgage loans and other mortgage related assets. Its investment portfolio also includes Re/Non-Performing Loans, Land Related Financing and Agency RMBS. Agency RMBS represent interests in pools of residential mortgage loans guaranteed by a GSE.


NYSE:MITT - Post by User

Post by LeaMileson Jun 03, 2022 5:35am
121 Views
Post# 34728791

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance



FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.



<< Previous
Bullboard Posts
Next >>